Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/11975
Title: | Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritides |
Authors: | MOTA, Licia Maria Henrique da; CRUZ, Boris Afonso; BRENOL, Claiton Viegas; POLLAK, Daniel Feldman; PINHEIRO, Geraldo da Rocha Castelar; LAURINDO, Ieda Maria Magalhaes; PEREIRA, Ivanio Alves; CARVALHO, Jozelio Freire de; BERTOLO, Manoel Barros; PINHEIRO, Marcelo de Medeiros; FREITAS, Max Victor Carioca; SILVA, Nilzio Antonio da; LOUZADA-JUNIOR, Paulo; SAMPAIO-BARROS, Percival Degrava; GIORGI, Rina Dalva Neubarth; LIMA, Rodrigo Aires Correa; ANDRADE, Luis Eduardo Coelho |
Citation: | REVISTA BRASILEIRA DE REUMATOLOGIA, v.55, n.3, p.281-309, 2015 |
Abstract: | The treatment of autoimmune rheumatic diseases has gradually improved over the last half century, which has been expanded with the contribution of biological therapies or immunobiopharmaceuticals. However, we must be alert to the possibilities of undesirable effects from the use of this class of medications. The Brazilian Society of Rheumatology (Sociedade Brasileira de Reumatologia) produced a document based on a comprehensive literature review on the safety aspects of this class of drugs, specifically with regard to the treatment of rheumatoid arthritis and spondyloarthritides. The themes selected by the participating experts, on which considerations have been established as the safe use of biological drugs, were: occurrence of infections (bacterial, viral, tuberculosis), infusion reactions, hematological, neurological, gastrointestinal and cardiovascular reactions, neoplastic events (solid tumors and hematologic neoplasms), immunogenicity, other occurrences and vaccine response. For didactic reasons, we opted by elaborating a summary of safety assessment in accordance with the previous themes, by drug class/mechanism of action (tumor necrosis factor antagonists, T-cell co-stimulation blockers, B-cell depletors and interleukin-6 receptor blockers). Separately, general considerations on safety in the use of biologicals in pregnancy and lactation were proposed. This review seeks to provide a broad and balanced update of that clinical and experimental experience pooled over the last two decades of use of immunobiological drugs for RA and spondyloarthritides treatment. |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - HC/ICHC Artigos e Materiais de Revistas Científicas - LIM/17 Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_MOTA_Safe_use_of_biological_therapies_for_the_treatment_2015.PDF | publishedVersion (English) | 3.13 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.